

February 23, 2015

As of February 20, Novozymes has purchased an accumulated 604,000 shares with a transaction value of DKK 185.7 million under the stock buyback program Novozymes announced in Company announcement No. 6, 2015 and initiated February 2, 2015. Under the program, Novozymes will buy back B shares worth up to DKK 2 billion in total during 2015.

The following transactions have been made under the program in accordance with the provisions of European Commission Regulation (EC) No. 2273/2003 of 22 December 2003, also referred to as the Safe Harbour Regulation:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	449,000		136,684,003
16 February 2015	34,000	310.97	10,572,903
17 February 2015	36,000	312.65	11,255,333
18 February 2015	25,000	320.20	8,005,001
19 February 2015	30,000	319.03	9,570,892
20 February 2015	30,000	318.99	9,569,692
Accumulated under the program	604,000		185,657,824

In addition, transactions necessitated by Novozymes' previously established incentive programs have resulted in a net sale by Novozymes of 21,950 B shares in the period from February 16 to February 20, 2015. The share transactions related to the incentive programs were not part of the Safe Harbour stock buyback program.

Following the transactions stated above, Novozymes owns a total of 11,336,399 treasury shares, corresponding to 3.5% of the stock capital. The total number of shares in the company is 319,700,000, including treasury shares.

Contact information

Thomas Bomhoff (DK)	+45 3077 1226	tsbm@novozymes.com
Klaus Sindahl (DK)	+45 5363 0134	ksdh@novozymes.com
Martin Riise (USA)	+1 919 649 2565	mrsn@novozymes.com

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com.

Page 1 of 1